Type 2 Diabetes Mellitus Completed Phase 1 Trials for Sitagliptin (DB01261)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus´╝îType 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00642798An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)Treatment
NCT02749032Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) SecretionTreatment
NCT00541229Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)Treatment
NCT00730275A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)Treatment
NCT00961480A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)Treatment
NCT00961857A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)Treatment
NCT00971659Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 DiabetesTreatment
NCT00975052A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)Treatment
NCT01093794Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)Treatment
NCT01557504A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)Treatment
NCT00888238A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)Diagnostic
NCT00551590Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes MellitusDiagnostic
NCT00830076A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)Treatment
NCT00842556Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
NCT00929201Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)Treatment
NCT01095991Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes MellitusTreatment
NCT01422590Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and SitagliptinTreatment
NCT01441232A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsTreatment
NCT01582308A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)Treatment
NCT00511108Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)Treatment
NCT00704132Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)Treatment
NCT00813228Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy IndividualsTreatment
NCT02827890CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)Treatment
NCT03115099A Study of LY3325656 in Healthy Participants and Participants With Type 2 DiabetesBasic Science
NCT01408888A Study of LY2189265 and Sitagliptin in Participants With Type 2 DiabetesTreatment
NCT00976261A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 DiabetesTreatment
NCT00871507A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes MellitusTreatment
NCT01054118A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and SitagliptinTreatment